Get to know our clinical trials
Debio 0123 trial in adult patients with advanced solid tumors
THE OBJECTIVES OF THIS STUDY ARE: ¿ TO PROVE THAT DEBIO 0123 HAS NO SIGNIFICANT SIDE EFFECTS. ¿ TO DETERMINE WHETHER DEBIO 0123 EXERTS CERTAIN EFFECTS ON THE TUMOR MASS. ¿ TO DETERMINE HOW DEBIO 0123 IS BROKEN DOWN IN THE BODY. ¿ TO DETERMINE WHETHER THERE ARE GENETIC FACTORS OR TUMOR-SPECIFIC CHARACTERISTICS THAT MAY HELP CLARIFY IN WHOM DEBIO 0123 WORKS BEST.
Technical Summary
- PHASE 1 DOSE-FINDING STUDY OF DEBIO 0123 IN MONOTHERAPY IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS, FOLLOWED BY AN EXTENSION PART TO ASSESS SAFETY AND PRELIMINARY ANTITUMOR ACTIVITY.
- Code EudraCT: 2023-504824-24
- Protocol number: Debio 0123-102
- Promoter: Debiopharm International S.A.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.